RecurX Bio is leading the way in providing personalized information to oncologists to choose the best cancer drugs to stop metastatic cells before treatment begins. Our patented, microfluidic, phenotypic assay reproduces in the lab what happens in the body. The assay cost-effectively and within a 2 days captures the most deadly cancer cells responsible for metastasis. We have multiple $1B markets for patients and services to pharma companies.